Mr. Cameron Groome reports
MICROBIX ANNOUNCES QUALITY PRODUCTS DISTRIBUTION AGREEMENT
Microbix Biosystems Inc. has appointed Labquality Oy as a distributor of its quality assessment products (QAPs) in seven countries.
Under an agreement between the parties, Labquality has been appointed as distributor of Microbix's quality assessment products (QAPs) for Denmark, Estonia, Finland, Latvia, Lithuania, Poland and Sweden. As distributor, Labquality will provide marketing, distribution and logistical support for Microbix's QAPs. At present, there are four dozen such QAPs across the Proceedx and Redx controls trade names -- to support whole-process accuracy of tests for bacterial and viral diseases by emulating patient samples while being consistent, non-infectious, stable and cross-instrument compatible.
Based in Helsinki, Labquality is a Finnish owned and operated life sciences company that provides clinical laboratories with external quality assessment (EQA) programs to evaluate their proficiency and attain necessary accreditations. Labquality also provides quality controls (QAPs) and other reference materials to support the internal quality management systems of clinical laboratories. Labquality services approximately 6,500 customers in over 50 countries and maintains an extensive network of subdistributors of its products and programs.
Labquality will incorporate Microbix's QAPs into its EQA programs and sell Proceedx and Redx controls branded QAPs directly to its clinical laboratory customers. This will include Microbix's QAPs to support the accuracy of testing for respiratory viruses such as SARS-CoV-2 (COVID-19), flu A, flu B and RSV, as well as its leading-edge QAPs for high-risk types of HPV and other sexually transmitted infections. Labquality already services clinical labs in the territories and is well positioned to distribute the full QAPs catalogue.
Cameron Groome, chief executive officer and president of Microbix, stated: "We're pleased to have Labquality become our distribution partner for QAPs product lines for Scandinavia and Northern Europe. As an established proficiency testing program provider and product distributor in the region, they are highly respected and well known by both hospital and stand-alone labs. Our controls are therefore a natural addition to their product offerings and we are convinced the agreement will be successful for both our companies."
Mia Lindstrom, managing director of Labquality, also commented: "We're pleased to secure access to Microbix's innovative QAPs for our laboratory customers. There is an ever-increasing need to improve the accuracy of clinical diagnostic testing that these products will help address. Training of Labquality staff about QAPs is already well advanced and we are now beginning to stock this product portfolio."
About Microbix Biosystems Inc.
Microbix develops proprietary biological and technology solutions for human health and well-being, with sales now exceeding $1-million per month on average and approximately 80 skilled employees. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure quality control of clinical diagnostic tests.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.